Bardet-Biedl Syndrome
11
3
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
9.1%
1 terminated out of 11 trials
83.3%
-3.2% vs benchmark
18%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)
Early Genetic Identification of Obesity
Characterizing the Genotype and Phenotype in Adults With Bardet-Biedl Syndrome
Inherited Retinal Degenerative Disease Registry
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Clinical Registry Investigating Bardet-Biedl Syndrome
COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study
Genetics and Clinical Characteristics of Bardet-Biedl Syndrome
Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement
Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in Adults